Skip to Content

Sartorius Stedim Biotech SA SDMHF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Sartorius Stedim Biotech is the leading provider of tools for biopharmaceutical fermentation and fluid management. Parent Sartorius AG has a 74% stake in the company, with 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (40% of 2020 sales), the Americas (35%), and Asia-Pacific (25%). Sartorius Stedim Biotech employs over 7,500 people and has operations in more than 20 countries.

Contact
Otto-Brenner-Str. 20
Goettingen, 37079, France
T +49 5513080
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 6,900